“These studies demonstrated that OAV101 was well tolerated at this dose level up to 12 months post injection, with minor microscopic findings reported 6 weeks post-administration in the dorsal root ganglia (DRG), spinal cord, peripheral nerves, and brain that did not increase in severity or incidence over the 12 month study.”
✓ VerifiedFDA summary basis for approval, p. 15Source ↗
Pivotal GLP studies
Single-dose IT NHP study (1.2, 3.0, 6.0 x10^13 vg/animal) to 12 months; mouse ICV studies; IV mouse FEED and EFD
“A single IT dose of onasemnogene abeparvovec was administered at three dose levels: 1.20 × 10 13 vg/animal (equivalent to the clinical therapeutic dose), 3.0 × 10 13 vg/animal, and 6.0 × 10 13 vg/animal.”
“Additional single-dose studies in the newborn Friend Virus B (FVB) mouse strain and NHPs further demonstrated high tolerability to OAV101 or scAAV9.CBA.SMN following ICV or IT administration, respectively, with no major safety signals.”
✓ VerifiedFDA summary basis for approval, p. 16Source ↗